Delving into the Latest Updates on Curium Finland Oy with Synapse

Overview

AbstractYttrium-90 (90Y) has attracted much research attention in targeted radionuclide therapy because its many favorable properties and availability from a long shelf-life generator system. Although numerous generator systems have been developed for the production of 90Y, a common disadvantage is that the 90Y is not eluted in an ionic form suitable for direct labeling of chelating agents bound to useful targeting molecules. In this study, we have adapted previously published procedures and developed a 740 MBq (20 mCi) of generator system in which the parent activity 90Sr was retained on a cation exchange resin, while the daughter 90Y activity was eluted with acetate buffer solution and used directly to label useful radioconjugates without further manipulations. A safety column, not loaded with 90Sr, was connected in series with the generator resulting in an eluate free of any 90Sr breakthrough for at least eight months. The features of this new generator make it suitable for clinical applications.

Radioisotope production at JYFL accelerator Laboratory in Finland

Author: Julin, R. ; Nieminen, V. ; Liukkonen, E. ; Hiltunen, J. ; Kumpulainen, J. ; Aysto, J. ; Poikolainen, T.

Radioisotope production at the title laboratory is described for nuclear medicine applications.Features of the production facility are detailed.

Tritium labeling of benzodiazepines and some related compounds

Author: Peng, C. T. ; Williams, P. G. ; Hiltunen, J.

A symposium report with 10 references on the tritiation of benzodiazepines using the high-temperature tritium ion method.

100 Deals associated with Curium Finland Oy

Login to view more data

100 Translational Medicine associated with Curium Finland Oy

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data